| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,074 |
1,020 |
$51K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
670 |
633 |
$50K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
857 |
815 |
$49K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,014 |
985 |
$48K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
326 |
314 |
$28K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
857 |
815 |
$12K |
| 87428 |
|
199 |
194 |
$6K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
136 |
132 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
236 |
224 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
120 |
97 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
58 |
28 |
$632.34 |
| 81003 |
|
18 |
15 |
$29.25 |
| H0033 |
Oral medication administration, direct observation |
12 |
12 |
$0.00 |